Drug Trial Radar · NCT04535986
A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
Last checked: Nov 20, 2026Latest source record: Nov 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
763
Actual
Start
Sep 29, 2020
Primary completion
Sep 12, 2022
Study completion Dec 2, 2022
Sponsor
- Lead sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USAIndustry
- Sponsor type
- Industry
- Collaborators
- IQVIA Pty Ltd
- First posted
- Sep 2, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of ensifentrine in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).
Conditions
- Chronic Obstructive Pulmonary Disease
Interventions
EnsifentrineDrug
Dosage Formulation: Ensifentrine Nebulizer suspension Dosage 3mg Frequency: Twice Daily for 24 weeks or 48 weeks
PlaceboDrug
Dosage Formulation: Ensifentrine Placebo Nebulizer solution Frequency: Twice Daily for 24 weeks or 48 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Least Square (LS) Mean Change From Baseline in Average Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve Over 12 Hours (AUC0-12h) at Week 12Time frame: Baseline (pre-dose on Day 1) and Week 12
Locations
122 sites in 12 countries. Site status is shown where the registry gives one.
Phoenix Medical Group
Peoria, Arizona
AMR Tempe
Tempe, Arizona
Beach Physicians Medical Group
Huntington Beach, California
Downtown LA Research Center, Inc.
Los Angeles, California
Clinical Research of West Florida, Inc.
Clearwater, Florida
St. Francis Medical Institute
Clearwater, Florida
Qway Research, LLC
Hialeah, Florida
Multi-Specialty Research Associates, Inc.
Lake City, Florida
Elite Clinical Research
Miami, Florida
Global Research Solutions Corp
Miami, Florida
Phoenix Medical Research
Miami, Florida
Florida Institute for Clinical Research
Orlando, Florida
Precision Clinical Research
Sunrise, Florida
Clinical Research of West Florida, Inc.
Tampa, Florida
iResearch Atlanta, LLC
Decatur, Georgia
IACT Health
Rincon, Georgia
In-Quest Medical Research, LLC
Suwanee, Georgia
John Hopkins University School of Medicine
Baltimore, Maryland
Pulmonary Research Institute of SE Michigan
Farmington Hills, Michigan
Midwest Chest Consultants
Saint Charles, Missouri
The Clinical Research Center, LLC
St Louis, Missouri
Sierra Clinical Research
Las Vegas, Nevada
Alliance for Multispecialty Research, LLC
Las Vegas, Nevada
IMA Clinical Research, LLC
New York, New York
Monroe Biomedical Research
Monroe, North Carolina
Remington Davis Clinical Research
Columbus, Ohio
Velocity Clinical Research - Grants Pass
Grants Pass, Oregon
Clinical Research Associates of Central PA, LLC
DuBois, Pennsylvania
University of Pittsburgh Physicians, Emphysema/COPD Research Center
Pittsburgh, Pennsylvania
Medtrial
Columbia, South Carolina
MDFirst Research
Lancaster, South Carolina
Chattanooga Research & Medicine (CHARM)
Chattanooga, Tennessee
MultiSpecialty Clinical Research, Inc.
Johnson City, Tennessee
New Phase Research Development
Knoxville, Tennessee
West Houston Clinical Research Services
Houston, Texas
LinQ Research, LLC
Pearland, Texas
Sherman Clinical Research
Sherman, Texas
Pulmonary Research of Abingdon, LLC
Abingdon, Virginia
TPMG Clinical Research Williamsburg
Williamsburg, Virginia
SHATPPD - Haskovo, EOOD
Haskovo, Bulgaria
Showing 40 of 122 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.